To Assess the Safety and Tolerability of MTx-COVAB36 as a Therapeutic and Prophylactic Treatment Against COVID-19.

NCT05351437 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

32

Enrollment

INDUSTRY

Sponsor class

Conditions

SARS-CoV-2 Infection

Interventions

DRUG: MTx-COVAB36
DRUG: Placebo

Sponsor

Memo Therapeutics AG